Reinach, Switzerland, 18 May 2011 –The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors, including those regarding the Company’s intended acquisition of its R&D partner Abunda Nutrition, Inc.
A total of 85 shareholders were present at the meeting which took place in Basel today. 100,379,115 shares were represented, or 71.9% of the total number of shares issued (139,665,164). A detailed overview of the agenda items and the proposals is available on the Evolva website.
The AGM proposals included increases in conditional and authorised capital in Evolva’s Articles of Association. The shareholders’ approval of these items clears the way for the closing of Evolva’s acquisition of Abunda Nutrition, Inc. This transaction is expected to take place around the end of June 2011.
About Evolva
Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people’s lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications. For more information visit www.evolva.com.
Contact Details
Evolva
Neil Goldsmith, CEO Jakob Dynnes Hansen, CFO Paul Verbraeken, IR
neilg@evolva.com
jakobdh@evolva.com
paulv@evolva.com
+ 41 61 485 2005 + 41 61 485 2034 + 41 61 485 2035
Capital MSL
Mary Clark, Justine Lamond and Hollie Vile
evolva@capitalmsl.com
+44 (0)20 7307 5337
